[go: up one dir, main page]

BRPI0813140C1 - método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário - Google Patents

método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário

Info

Publication number
BRPI0813140C1
BRPI0813140C1 BRPI0813140A BRPI0813140A BRPI0813140C1 BR PI0813140 C1 BRPI0813140 C1 BR PI0813140C1 BR PI0813140 A BRPI0813140 A BR PI0813140A BR PI0813140 A BRPI0813140 A BR PI0813140A BR PI0813140 C1 BRPI0813140 C1 BR PI0813140C1
Authority
BR
Brazil
Prior art keywords
preparation
dca
ester
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0813140A
Other languages
English (en)
Inventor
Rathan Prasad Achampeta
Kumar Sahoo Akhila
Gregory Reid John
Ahmeduddin Mahmood Nadir
E David Nathaniel
M Moriarty Robert
A Swaringen Roy Jr
Original Assignee
Kythera Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813140(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/035,339 external-priority patent/US20080318870A1/en
Priority claimed from GB0807615A external-priority patent/GB2452358C/en
Application filed by Kythera Biopharmaceuticals Inc filed Critical Kythera Biopharmaceuticals Inc
Publication of BRPI0813140A2 publication Critical patent/BRPI0813140A2/pt
Publication of BRPI0813140B1 publication Critical patent/BRPI0813140B1/pt
Publication of BRPI0813140C1 publication Critical patent/BRPI0813140C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição, método, e preparação de ácido biliar sintético ácidos biliares e composições e métodos relacionados de síntese e uso. mais especificamente, ácido desoxicólico e composições relacionadas, as referidas composições sendo livres de porções de origem animal e livres de porções pirogênicas.
BRPI0813140A 2007-06-19 2008-06-18 método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário BRPI0813140C1 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US94503507P 2007-06-19 2007-06-19
US95687507P 2007-08-20 2007-08-20
US12/035,339 US20080318870A1 (en) 2007-06-19 2008-02-21 Synthetic bile acid compositions and methods
GB0807615A GB2452358C (en) 2008-04-25 2008-04-25 Preparation of bile acids.
US12/153,446 US7902387B2 (en) 2008-04-25 2008-05-16 Preparation of bile acids and intermediates thereof
PCT/US2008/067391 WO2008157635A2 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation

Publications (3)

Publication Number Publication Date
BRPI0813140A2 BRPI0813140A2 (pt) 2014-12-23
BRPI0813140B1 BRPI0813140B1 (pt) 2019-02-05
BRPI0813140C1 true BRPI0813140C1 (pt) 2021-05-25

Family

ID=41226994

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813140A BRPI0813140C1 (pt) 2007-06-19 2008-06-18 método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário

Country Status (28)

Country Link
EP (3) EP2407475B1 (pt)
JP (2) JP2010530876A (pt)
KR (7) KR101598402B1 (pt)
CN (4) CN106146594A (pt)
AR (1) AR067440A1 (pt)
AU (1) AU2008265721B2 (pt)
BR (1) BRPI0813140C1 (pt)
CA (2) CA2690841C (pt)
CR (2) CR20170070A (pt)
CY (1) CY1116700T1 (pt)
DK (1) DK2407475T3 (pt)
EA (1) EA020806B1 (pt)
ES (2) ES2826429T3 (pt)
HR (1) HRP20150879T1 (pt)
HU (1) HUE025909T2 (pt)
IL (1) IL202203B (pt)
JO (1) JO3172B1 (pt)
MX (2) MX2009013664A (pt)
MY (1) MY160040A (pt)
NZ (1) NZ581081A (pt)
PH (1) PH12013500364A1 (pt)
PL (1) PL2407475T3 (pt)
PT (1) PT2407475E (pt)
SI (1) SI2407475T1 (pt)
SM (1) SMP201000003B (pt)
TW (2) TWI503396B (pt)
WO (1) WO2008157635A2 (pt)
ZA (1) ZA200907928B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
BRPI0813140C1 (pt) * 2007-06-19 2021-05-25 Kythera Biopharmaceuticals Inc método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
GB2480632A (en) * 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
MX2013001704A (es) * 2010-08-12 2013-06-28 Kythera Biopharmaceuticals Inc Composiciones sinteticas de acido biliar y metodos.
EP3138850B8 (en) * 2011-06-16 2019-09-11 Allergan Sales, LLC Compositions containing deoxycholic acid and 10% deionized water in ethanol, directed to the purification of deoxycholic acid
US20130102580A1 (en) * 2011-09-22 2013-04-25 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
US10081592B2 (en) 2012-03-23 2018-09-25 The Board Of Trustees Of The University Of Illinois Complex and structurally diverse compounds
CN103059087B (zh) * 2012-12-30 2015-10-14 中山百灵生物技术有限公司 一种脱氧胆酸的合成方法
KR101447901B1 (ko) * 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
MA43066A (fr) * 2015-07-30 2018-06-06 Intercept Pharmaceuticals Inc Procédés de préparation d'acides biliaires et de leurs dérivés
CN108366975A (zh) * 2015-11-04 2018-08-03 凯瑟拉生物制药有限公司 使用脱氧胆酸和其盐对堆积的脂肪的治疗
KR102527103B1 (ko) * 2016-06-06 2023-04-28 크리스탈 파마 에스.에이.유. 디옥시콜린산 제조방법 및 디옥시콜린산의 제조에 유용한 중간물
CN111328332B (zh) * 2017-08-03 2023-01-24 玫帝托克斯股份有限公司 用于制备胆汁酸类的方法
WO2019081586A1 (en) 2017-10-24 2019-05-02 Bionice, S.L.U. PREPARATION OF DEOXYCHOLIC ACID
RU2705314C1 (ru) * 2019-03-18 2019-11-06 Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) Способ производства сухих очищенных солей желчных кислот для бактериологии
KR102456989B1 (ko) * 2020-06-12 2022-10-21 (주)케어젠 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도
EP4215540A4 (en) * 2020-09-18 2025-01-15 Seoul National University R & DB Foundation METHOD FOR MASS PRODUCTION OF SODIUM TAURODEOXYCHOLATE
JP2024525831A (ja) 2021-07-16 2024-07-12 スカイ・セラピューティクス・カンパニー・リミテッド 胆汁酸または胆汁酸塩の分子会合体及びこれを含む局所脂肪除去用の医薬組成物
CN117979950A (zh) 2021-07-16 2024-05-03 思凯制药有限公司 包含胆汁酸或胆汁酸盐的分子聚集体的化妆品组合物
CN114478676B (zh) * 2022-02-18 2024-05-10 国药集团化学试剂有限公司 一种脱氧胆酸钠的制备方法
CN115974949B (zh) * 2022-10-26 2023-12-22 湖南科瑞生物制药股份有限公司 一种植物源脱氧胆酸中间体的制备方法
CN118344420A (zh) * 2023-01-16 2024-07-16 北京诺博特生物科技有限公司 一种脱氧胆酸的制备方法
WO2025175304A2 (en) 2024-02-16 2025-08-21 Sanofi Pasteur Inc. Process for the preparation of deoxycholic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2321598A (en) * 1940-10-07 1943-06-15 George A Breon & Company Inc Preparation of desoxycholic acid
US2615902A (en) * 1950-10-24 1952-10-28 Merck & Co Inc Chemical compounds and processes for preparing the same
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4866044A (en) * 1985-07-09 1989-09-12 Takeda Chemical Industries, Ltd. Solubilized composition of poorly-soluble pharmaceutical product
KR0138777B1 (ko) * 1988-04-08 1998-04-30 쟝 끌로드 비에유포스 9α-히드록시-17-메틸렌 스테로이드, 그의 제조방법 및 코르티코스테로이드 제조에의 이용
FR2754709B1 (fr) * 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
SI2422789T1 (en) * 2004-05-19 2018-07-31 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injectable coposition comprising sodium deoxycholate
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
WO2006133160A2 (en) * 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
BRPI0813140C1 (pt) * 2007-06-19 2021-05-25 Kythera Biopharmaceuticals Inc método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário

Also Published As

Publication number Publication date
AU2008265721A1 (en) 2008-12-24
KR20180061401A (ko) 2018-06-07
KR101863131B1 (ko) 2018-06-01
AR067440A1 (es) 2009-10-14
EA201000032A1 (ru) 2010-04-30
TW201534684A (zh) 2015-09-16
PL2407475T3 (pl) 2015-12-31
CR11174A (es) 2010-03-23
IL202203A0 (en) 2010-06-16
CN106083969B (zh) 2018-02-27
IL202203B (en) 2018-04-30
JP2013075918A (ja) 2013-04-25
KR20100031512A (ko) 2010-03-22
CN108191940B (zh) 2021-02-09
DK2407475T3 (en) 2015-10-26
JP2010530876A (ja) 2010-09-16
CA2690841A1 (en) 2008-12-24
HRP20150879T1 (hr) 2015-09-25
NZ581081A (en) 2012-12-21
SMAP201000003A (it) 2010-03-01
BRPI0813140A2 (pt) 2014-12-23
TW200918550A (en) 2009-05-01
PT2407475E (pt) 2015-11-20
PH12013500364A1 (en) 2014-04-28
EP2407475A2 (en) 2012-01-18
SMP201000003B (it) 2010-11-12
TWI503396B (zh) 2015-10-11
EP3002290A3 (en) 2016-06-29
HK1223372A1 (en) 2017-07-28
EP2407475A3 (en) 2012-06-13
KR20160025044A (ko) 2016-03-07
CR20170070A (es) 2017-04-27
MY160040A (en) 2017-02-15
JO3172B1 (ar) 2018-03-08
AU2008265721B2 (en) 2014-03-20
KR20180122483A (ko) 2018-11-12
CA2690841C (en) 2012-11-27
CN106083969A (zh) 2016-11-09
EA020806B1 (ru) 2015-01-30
EP2069383A2 (en) 2009-06-17
HK1165807A1 (en) 2012-10-12
EP3002290B1 (en) 2020-09-09
BRPI0813140B1 (pt) 2019-02-05
KR101916024B1 (ko) 2018-11-08
WO2008157635A2 (en) 2008-12-24
CA2789109C (en) 2015-10-06
KR20130133881A (ko) 2013-12-09
WO2008157635A3 (en) 2009-06-04
CN106146594A (zh) 2016-11-23
TWI503327B (zh) 2015-10-11
KR101598402B1 (ko) 2016-03-03
KR20160150646A (ko) 2016-12-30
HUE025909T2 (en) 2016-04-28
KR102061001B1 (ko) 2020-01-03
ZA200907928B (en) 2011-05-28
KR20150013305A (ko) 2015-02-04
EP3002290A2 (en) 2016-04-06
CN108191940A (zh) 2018-06-22
SI2407475T1 (sl) 2016-03-31
ES2826429T3 (es) 2021-05-18
CN101711254A (zh) 2010-05-19
MX360094B (es) 2018-10-19
CY1116700T1 (el) 2017-03-15
EP2407475B1 (en) 2015-08-12
JP5589102B2 (ja) 2014-09-10
CA2789109A1 (en) 2008-12-24
MX2009013664A (es) 2010-04-07
ES2550504T3 (es) 2015-11-10

Similar Documents

Publication Publication Date Title
BRPI0813140C1 (pt) método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
BRPI0713357A2 (pt) Inibidores de proteína tirosina fosfatase humana e método de utilização.
CL2008001302A1 (es) Compuestos derivados de tetramatos sustituidos con 3-(2-alcoxifenilo); su proceso de preparacion de los mismos; agente para combatir plagas animales y/o vegetacion indeseada; procedimiento para su preparacion; uso de dichos compuestos; composicion que comprende a dichos compuestos; y procedimiento para combatir vegetacion indeseada.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0613429A2 (pt) inibidores de histona desacetilase
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
CL2010001530A1 (es) Compuestos derivados de tiadiazoliloxifenilamidinas; su procedimiento de preparacion; agentes para combatir microorganismos indeseados que comprende a dichos compuestos; uso; procedimiento para combatir microorganismos indeseados; y compuestos intermediarios.
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BRPI0702269A (pt) alcanolamidas e uso do mesmo como aditivos de combustìvel
WO2007118205A3 (en) Compounds, compositions and methods for treating hormone-dependent maladies
WO2012078546A3 (en) Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
CU20110185A7 (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad glucocorticoide
MX2011012479A (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
NZ600263A (en) 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
BRPI0719529B8 (pt) método para produzir uma preparação sólida
EA200901030A1 (ru) Антагонист хроменового рецептора s1p1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2509 DE 05/02/2019, QUANTO A PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2727 DE 11-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.